Form 4: Day One Biopharmaceuticals Executive Samuel C. Blackman Reports Stock Transactions
SEC Form 4 Filing
Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, reports acquisition and disposal of company stock and derivative securities to cover tax liabilities.
Summary
- On May 15 and 16, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, engaged in transactions involving the company's common stock and Restricted Stock Units (RSUs).
- Blackman acquired shares through the vesting of RSUs and disposed of some shares to cover tax liabilities associated with the RSU settlements.
- Specifically, on May 15, 2024, Blackman acquired 1,187, 1,437, and 6,062 shares of common stock through RSU conversions.
- On May 16, 2024, Blackman sold 2,267 shares at a price of $16.0787 per share.
- Following these transactions, Blackman directly owns 1,171,081 shares and indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC.
- He also holds derivative securities in the form of RSUs, with varying amounts vesting quarterly.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and tax obligations, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
- Executive compensation often includes stock options and RSUs, leading to regular Form 4 filings when these instruments are exercised or vest.
- The sale of shares to cover tax liabilities is a common occurrence among executives receiving equity compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to routine executive compensation and tax obligations.
- Shareholders may monitor insider transactions for insights into management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Acquisition of common stock through RSU conversions. |
| 05/16/2024 | Sale of common stock to cover tax liabilities. |
| 05/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.